Lamin and the heart.

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Nuclear Envelope Biology

Background:

• Mutations in the LMNA gene, encoding lamins A and C, are a significant cause of inherited dilated cardiomyopathy (DCM), accounting for 10% of cases.
• Lamin A/C heart disease presents with progressive conduction system disease, arrhythmia, and systolic impairment, often with a more severe clinical course than other DCM types.
• This condition is potentially under-recognized due to phenotypic mimics, despite a high probability of LMNA mutations in familial DCM with early conduction disease.

Purpose of the Study:

• To review the biology, clinical presentation, screening, and management of lamin A/C heart disease.
• To highlight the importance of recognizing LMNA-related cardiomyopathy for early intervention with devices and novel therapies.
• To discuss the integration of genetic, functional, and pathological data in advancing the understanding of LMNA variants.

Main Methods:

• Review of current literature on LMNA gene mutations and associated cardiomyopathies.
• Analysis of clinical presentations, diagnostic pointers, and imaging features.
• Discussion of genotype-phenotype correlations and emerging therapeutic strategies.

Main Results:

• LMNA mutations lead to a distinct and aggressive form of DCM requiring early intervention.
• Integrated approaches combining genetic, in vivo cardiomyocyte mechanics, and nuclear envelope pathology are crucial for understanding LMNA variants.
• Research into MAPK pathways suggests promising oral drug therapies and personalized treatment approaches.

Conclusions:

• Early identification of lamin A/C heart disease is critical for timely implantation of cardioverter defibrillators.
• Personalized risk stratification and heart failure therapy are becoming feasible for LMNA-related cardiomyopathies.
• Continued research integrating diverse data types is essential for advancing knowledge and improving patient outcomes.